Characteristics | Number | Partial response | Stable | Progressive | P-value |
Over all | 106 | 51 | 47 | 8 | |
Age | |||||
≤60 | 44 | 24 (54.5%) | 16 (36.4%) | 4 (9.1%) | 0.304 |
>60 | 62 | 27 (43.6%) | 31 (50.0%) | 4 (6.5%) | |
Performance Status | |||||
0 & 1 | 19 | 13 (68.4%) | 6 (31.6%) | 0 (0.0%) | 0.092 |
2 & 3 | 87 | 38 (43.7) | 41 (47.1%) | 8 (9.2%) | |
Pathology | |||||
Squamous cell carcinoma | 56 | 21 (37.5%) | 30 (53.6%) | 5 (8.9%) | 0.230 |
Adenoc arcinoma | 37 | 23 (62.2%) | 12 (32.4%) | 2 (5.4%) | |
Large cell carcinoma | 13 | 7 (53.8%) | 5 (38.5%) | 1 (7.7%) | |
Grade | |||||
G2 | 59 | 31 (52.5%) | 27 (45.8%) | 1 (1.7%) | 0.039 |
G3 | 47 | 20 (42.6%) | 20 (42.6%) | 7 (14.9%) | |
T-stage | |||||
T2 | 31 | 19 (61.3%) | 9 (29.0%) | 3 (9.7%) | 0.109 |
T3 | 66 | 30 (45.5%) | 31 (47.0%) | 5 (7.6%) | |
T4 | 9 | 2 (22.2%) | 7 (77.8%) | 0 (0.0%) | |
Radical treatment type (62/106) | |||||
Radical radiotherapy | 2 | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | 0.324 |
Concomitant chemo-radiotherpy | 28 | 22 (78.6%) | 6 (21.4%) | 0 (0.0%) | |
Sequential chemo-radiotherpy | 32 | 19 (59.4%) | 10 (31.2%) | 3 (9.4%) | |
Treatment type (Radical vs. Palliative) | |||||
Palliative treatment | 44 | 9 (20.5%) | 30 (68.2%) | 5 (11.4%) | <0.001 |
Radical treatment | 62 | 42 (67.7%) | 17 (27.4%) | 3 (4.8%) | |
Hemoglobin | |||||
<11 mg/dl | 26 | 6 (23.1%) | 16 (61.5%) | 4 (15.4%) | 0.008 |
≥11 mg/dl | 80 | 45 (56.2%) | 31 (38.8%) | 4 (5.0%) | |
Radiotherapy technique | |||||
2D | 91 | 42 (46.2%) | 41 (45.1%) | 8 (8.8%) | 0.386 |
3D | 15 | 9 (60%) | 6 (40%) | 0 (0%) | |
Mass size | |||||
<7 cm | 41 | 28 (68.3%) | 10 (24.4%) | 3 (7.3%) | 0.002 |
>7 cm | 65 | 23 (35.4%) | 37 (56.9%) | 5 (7.7%) |